Welcome to our dedicated page for Gh Research Plc SEC filings (Ticker: GHRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GH Research PLC filings document foreign private issuer current reports for a clinical-stage biopharmaceutical company developing mebufotenin product candidates for depression. The company’s Form 6-K reports furnish press releases, corporate presentations, manuscripts, and conference materials related to GH001 in treatment-resistant depression, including Phase 2b results, open-label extension data, and FDA/IND regulatory updates.
The filing record also covers operating and financial results, material-event disclosures, shareholder voting matters, capital-structure information, material agreements, and clinical or regulatory disclosures. These documents describe the company’s research and development focus, product-candidate pipeline, governance reporting, and formal exhibits used to communicate trial publications and business updates.
GH Research PLC reports new clinical data on its inhaled mebufotenin product candidate GH001 for treatment-resistant depression, based on posters presented at the American Society of Clinical Psychopharmacology meeting.
In a Phase 2b randomized trial, GH001 produced rapid and large improvements in depression severity and anhedonia versus placebo. MADRS anhedonia factor scores fell by 9.9 points at Day 8 with GH001 versus 0.0 with placebo, with a Cohen’s d of −2.00 and changes exceeding published clinically meaningful thresholds. Benefits in illness severity, anxiety, and quality of life were statistically significant at Day 8 and were maintained in patients completing a 6‑month open-label extension, where anhedonia factor change averaged −12.2 points and 66.7% of patients were rated normal on CGI-S.
GH Research PLC: Lynx1 Capital Management and Weston Nichols report beneficial ownership of 10,763,288 Ordinary Shares, representing 17.4% of the class. This percentage is calculated from 62,029,395 Ordinary Shares outstanding as of February 17, 2026, per the company's Form 20-F. The filing states the Lynx1 Fund holds the shares and has the right to receive dividends and sale proceeds.
GH Research PLC ownership disclosure: Lynx1 Capital Management and Weston Nichols report beneficial ownership of 9,456,622 Ordinary Shares, representing 15.2% of the class. The percentage is calculated using 62,029,395 Ordinary Shares outstanding as of February 17, 2026.
The filing states the shares are directly held by the Lynx1 Master Fund LP and a managed account. Reported voting and dispositive authority is shared: Shared Voting Power 9,456,622 and Shared Dispositive Power 9,456,622. The statement is signed by Weston Nichols on behalf of Lynx1 and personally.
GH Research PLC has entered into an at-the-market equity offering sales agreement with Stifel, Nicolaus & Company to sell up to $200 million of ordinary shares. These shares, each with a nominal value of $0.025, may be sold from time to time as at-the-market offerings under an effective Form F-3 shelf registration.
The company filed a prospectus supplement dated May 14, 2026, together with an accompanying base prospectus dated March 7, 2025, to cover these potential sales. The filing also includes an Irish legal opinion on the validity of the shares and a related consent, and it incorporates this report by reference into several existing Form S-8 and Form F-3 registration statements.
GH Research PLC files a shelf registration to offer up to $400,000,000 of ordinary shares, debt securities, warrants, units or subscription rights from time to time after effectiveness. The prospectus describes general terms and states specific terms will be provided in prospectus supplements.
The company is a clinical-stage biopharmaceutical developer of inhalable and IV mebufotenin candidates (GH001, GH002). It reports 68,608,919 ordinary shares outstanding as of May 12, 2026 and lists its ordinary shares on Nasdaq under the symbol GHRS.
GH Research PLC intends to offer up to $200,000,000 of ordinary shares through an at‑the‑market sales agreement with Stifel, acting as agent. The prospectus supplement states sales may occur from time to time at prevailing market prices (the Agent may receive up to 3.0% commission).
The supplement shows an illustrative share count of up to 9,285,051 shares assuming sales at $21.54 (the last reported Nasdaq sale on May 12, 2026) and reports 62,052,506 shares outstanding as of March 31, 2026.
GH Research PLC reported first quarter 2026 results showing a deeper net loss as it advances its depression pipeline, while maintaining a strong cash position. Net loss was $19.0 million, or $0.31 per share, compared with $10.8 million, or $0.19 per share, a year earlier, driven mainly by higher research and development and professional fees.
R&D expenses rose to $12.4 million and G&A to $6.4 million, reflecting expanded technical and clinical work on lead inhaled mebufotenin candidate GH001 and supporting functions. Cash, cash equivalents and marketable securities totaled $267.3 million as of March 31, 2026, and the company subsequently received estimated net proceeds of $111.2 million from an April underwritten share offering, reinforcing liquidity.
GH Research highlighted publication of its GH001 Phase 2b TRD data in JAMA Psychiatry, where Day 8 remission rates ranged from 53.9% to 63.6% across subgroups, and completion of Phase 1 trials for its proprietary aerosol device and a U.S. IND-opening study. The company is seeking FDA alignment and continues to target initiation of a global Phase 3 pivotal program for GH001 in late 2026.
GH Research has filed a Form 6-K to circulate materials for its annual general meeting and provide its 2025 Irish statutory financial statements. The AGM will be held on 25 June 2026 at 1:30 pm (Irish Standard Time) in Dublin.
Shareholders will vote on the re-election of four non-executive directors and on ratifying PricewaterhouseCoopers Ireland as auditors, with the board authorized to set auditor pay. They will also receive and review, but not approve, the 2025 Irish accounts.
The directors’ report reiterates that GH Research is a clinical-stage biopharmaceutical company focused on mebufotenin-based therapies GH001 and GH002 for treatment-resistant depression and related disorders. The company reported net losses of $48.3 million in 2025 and $39.0 million in 2024, with an accumulated deficit of $154.4 million as of 31 December 2025 and no product revenue to date.
As of the AGM record date of 1 May 2026, there were 68,608,919 ordinary shares outstanding, each carrying one vote on a poll. The report emphasizes ongoing clinical, regulatory and funding risks and notes a prior FDA clinical hold on the GH001 IND that was lifted in December 2025 after additional toxicology and device work.
GH Research PLC, a foreign private issuer based in Dublin, Ireland, has filed a report indicating that it will attend the American Psychiatric Association Annual Meeting in San Francisco, California. The meeting is scheduled to take place from May 16 to May 20, 2026. The report is signed on behalf of the company by Julie Ryan, Vice President, Finance.